Skip to main content
KPC PHARMACEUTICALS, INC. logo

KPC PHARMACEUTICALS, INC. — Investor Relations & Filings

Ticker · 600422 ISIN · CNE0000015P8 LEI · 3003007ZALHXKUFMKN96 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 2,727 across all filing types
Latest filing 2023-11-03 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 600422

About KPC PHARMACEUTICALS, INC.

https://en.kpc.com.cn/

KPC Pharmaceuticals, Inc. specializes in the research, development, and manufacturing of pharmaceutical products, with a significant focus on natural and botanical medicines. The company is a global leader in the production of artemisinin-based anti-malarial treatments, including artemether and its derivatives. Its portfolio encompasses a wide range of therapeutic areas, notably cardiovascular and cerebrovascular health, where it utilizes Panax notoginseng saponins as a core component. KPC integrates traditional medicinal knowledge with modern pharmacological techniques to develop standardized botanical extracts and chemical drugs. The organization operates extensive production facilities and research centers dedicated to drug discovery and quality control. Its business activities extend to the distribution of healthcare products and the provision of medical services, aiming to provide comprehensive health solutions through innovation in natural medicine and biotechnology.

Recent filings

Filing Released Lang Actions
昆药集团关于注销部分募集资金专项账户的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from Kunming Pharmaceutical Group Co., Ltd. regarding the cancellation of part of the special account for raised funds from a 2015 private placement. It details the background of the fundraising, the management and storage of the funds, and the recent decision to close the special account and transfer remaining funds to the company's basic account. The document is relatively short (1612 characters) and serves as a formal notification about the status and management of fundraising accounts rather than a full financial report or audit. It does not contain financial statements or detailed financial analysis. Therefore, it is best classified as a Regulatory Filing (RNS), which is the fallback category for announcements that do not fit other specific categories.
2023-11-03 Chinese
昆药集团关于参与投资新设公司暨关联交易事项的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement from Kunming Pharmaceutical Group Co., Ltd. regarding its participation in the investment and establishment of a new company, Yunnan Sanqi Research Institute Co., Ltd., which involves related party transactions. It includes comprehensive information about the transaction, the parties involved, the investment amounts, the approval process by the board of directors, and risk analysis. The document is not a financial report, earnings release, or regulatory certification. It is a formal announcement of a capital investment and related party transaction, which fits the category of Capital/Financing Update (CAP). The document length (7801 characters) and detailed content confirm it is the announcement itself, not a brief notice or a report publication announcement.
2023-10-27 Chinese
昆药集团十届十九次监事会决议公告
Regulatory Filings Classification · 95% confidence The document is a supervisory board resolution announcement from Kunming Pharmaceutical Group regarding the approval of the company's 2023 third quarter report and an investment-related agenda item. It includes voting results and a written supervisory opinion on the third quarter report, confirming compliance with laws and regulations. The document is short (733 characters) and does not contain the actual financial statements or detailed financial data of the third quarter report but rather references that the report is published on the Shanghai Stock Exchange website. This fits the pattern of a regulatory announcement about a report rather than the report itself. Therefore, it should be classified as a Regulatory Filing (RNS).
2023-10-27 Chinese
昆药集团十届十九次董事会决议公告
Board/Management Information Classification · 95% confidence The document is a board resolution announcement from Kunming Pharmaceutical Group Co., Ltd. It details decisions made at the company's 19th board meeting of the 10th session, including approval of the 2023 third quarter report, investment participation, and election of a new strategic committee member. The document is short (732 characters) and primarily announces board decisions rather than providing detailed financial data or full reports. It is not a full quarterly report (IR) but a board/management information announcement about board resolutions and management decisions. Therefore, the appropriate classification is Board/Management Information (MANG).
2023-10-27 Chinese
（上网）昆药集团独立董事关于公司十届十九次董事会相关事项的事前认可及独立意见
Board/Management Information Classification · 95% confidence The document contains independent directors' opinions and approvals related to specific board meeting matters, specifically about an investment and related party transaction. It references compliance with governance rules and company articles, and it is dated around a specific board meeting. The content is focused on board-level approvals and independent directors' opinions rather than full financial data or report publication. The document length is short (825 characters), and it is not a report itself but an official statement related to board matters. Therefore, it fits best under Board/Management Information (MANG), which covers announcements of changes or opinions related to board decisions.
2023-10-27 Chinese
昆药集团2023年第三季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "2023 年第三季度报告" which translates to "2023 Third Quarter Report." It contains detailed financial data including balance sheets, profit and loss statements, cash flow statements, and management commentary for the third quarter of 2023. The document is approximately 15,000 characters long, indicating it is a full report rather than a brief announcement. The content includes unaudited financial statements for the quarter ending September 30, 2023, and covers comprehensive financial performance and business updates for the period. This matches the definition of an Interim / Quarterly Report (IR), which is a comprehensive financial report for a period shorter than a full fiscal year containing actual financial statements and substantive financial data and analysis. Therefore, the document should be classified as an Interim / Quarterly Report (IR).
2023-10-27 Chinese

Browse filings by year

26 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.